[D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro.
about
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease statesTargeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic ApproachActivation of neuromedin B-preferring bombesin receptors on rat glioblastoma C-6 cells increases cellular Ca2+ and phosphoinositidesMolecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cellsHeterologous desensitization of bombesin-induced mitogenesis by prolonged exposure to vasopressin: a post-receptor signal transduction block.Autocrine and paracrine signaling through neuropeptide receptors in human cancer.Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.Vasorelaxin: a novel arterial smooth muscle-relaxing eicosapeptide from the skin secretion of the Chinese piebald odorous frog (Odorrana schmackeri).Cholera toxin inhibits signal transduction by several mitogens and the in vitro growth of human small-cell lung cancerIn vitro effects of substance P analogue [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P on human tumour and normal cell growthEffects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude miceDevelopment of potent gastrin-releasing peptide antagonists having a D-Pro-psi(CH2NH)-Phe-NH2 C terminusPathogenesis of lung cancer: 100 year report.Neuropeptides as cellular growth factors: role of multiple signalling pathways.Neuropeptide growth factors.Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo.Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors.Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies.Neuroendocrine lung cancer: a receptor-mediated disease?Involvement of substance P and the NK-1 receptor in pancreatic cancer.Neuropeptide growth factors and cancer.Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines.Bombesin stimulation of mitogenesis. Specific receptors, signal transduction, and early events.[Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (antagonist G) induces AP-1 transcription and sensitizes cells to chemotherapy.Pulmonary neuroendocrine cells. Their secretory products and their potential roles in health and chronic lung disease in infancy.Pentapeptides for the treatment of small cell lung cancer: Optimisation by Nind-alkyl modification of the tryptophan side chainMetabolism of the broad-spectrum neuropeptide growth factor antagonist: [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P.Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism.[D-Arg(1),D-Trp(5,7,9),Leu(11)]Substance P inhibits bombesin-induced mitogenic signal transduction mediated by both G(q) and G(12) in Swiss 3T3cells.Bombesin receptor in membranes from Swiss 3T3 cells. Binding characteristics, affinity labelling and modulation by guanine nucleotides.Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition.Bombesin and bombesin antagonists: studies in Swiss 3T3 cells and human small cell lung cancer.[Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism.Differential modulation of bombesin-stimulated phospholipase C beta and mitogen-activated protein kinase activity by [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P.Two classes of antagonist interact with receptors for the mitogenic neuropeptides bombesin, bradykinin, and vasopressin.[D-Arg1,D-Trp5,7,9,Leu11]Substance P coordinately and reversibly inhibits bombesin- and vasopressin-induced signal transduction pathways in Swiss 3T3 cells.Homodimeric forms of bombesin act as potent antagonists of bombesin on Swiss 3T3 cells.[D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors.The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer
P2860
Q24643524-C9768B62-3ACB-4B72-90FA-F07582BD57B3Q28085005-5DE59F41-AC62-4D41-9A52-2017600F1A1AQ28581445-BCACB97D-ED1A-4B6D-A408-F86D28984984Q29465546-E7F1B034-43DD-44A7-BC43-B86458B9821AQ33853110-387C57DB-4F8F-421A-A2E9-44A223044D4DQ34225976-159E1527-BC98-4548-90FD-ADABB3D72A66Q34441682-FC1BF92A-6785-475A-8106-8CD6C8877177Q34475975-7CF0B704-5CB9-44F7-A934-6AFA4FB0605AQ34584459-C3581522-15DA-49AD-9148-D7E9DA8B7B3EQ35817358-46544985-22DC-44F5-A4CF-1F941D4D2071Q35993583-F9FA75F8-AB2F-41A7-8B47-3A4EA8EF74F3Q36080188-B2FE6141-E7FC-4F85-A172-7F679821CD20Q36140580-8DA25893-2388-4A28-8105-A0F7A1AF31A9Q36233709-DF622AAD-F907-460F-B7A1-47DD7A9B1E58Q36396935-1282D397-A8EC-411E-8026-3E49E8578CF3Q36535839-3A5A9447-BF4A-458E-9BD2-9395A3E49EF2Q36797357-3BF892E5-421F-4E89-B88A-60BD431F7B1BQ36876106-9D499AB1-DCB0-4409-B14A-2E5ABDF81895Q37230848-A2922B37-B563-49B3-8943-687A7489A834Q37548870-B79CDF8B-9AE4-4811-9F32-2EFBEA131891Q37617971-31782EB3-8260-4F42-B9C2-D3A513251524Q37664018-19F7330B-23F9-4ABF-91BB-3B64E785284BQ37715777-DFEC95A7-2E50-424D-B2D6-DE987B20CDFEQ37900027-30C97C36-2789-4F6F-92CB-5B90673B3E97Q38275715-54D39302-EAA8-41A2-B335-1B5A5A99FEEDQ38370108-7E6512B7-E4D6-44C1-8991-DDFA8F0C1B04Q38700858-B965134D-C996-4E24-9445-7E23EF54BB4FQ39991948-CE4EC14A-873C-4C9F-8E78-184A12573B11Q40809869-68C9BD38-B70C-4B7E-822D-480B68D1AA3AQ41745121-FD7BC3C9-9DBD-4219-90C1-BA779B40F19DQ41812705-34BBDE8B-BFAE-4F99-BE2C-1DE3EDC89DC1Q41842236-9894F281-3D81-4FD5-A4CE-2DFDB639DAD7Q41870097-B6253E56-1176-41A2-A5BC-5E47848970A3Q42029480-B5F8A84F-0465-4CD2-9753-ADB353AC03CBQ42477362-246D1E0B-F88C-4881-BDAF-7463EC1FA3D7Q42805845-FE8E9B1D-73D1-4925-B836-8EA0AD3C2ED1Q42807084-395D125E-BFDD-470F-896F-F1C78E6C2B8BQ42830245-15EC87E8-ED29-4091-8F4A-09702F05B2FDQ42832267-B87363BB-7B5A-4F3B-90A6-B9C6B7EE0211Q58914868-B8ABB8A1-81CE-498B-A768-BCB353862D73
P2860
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro.
description
1988 nî lūn-bûn
@nan
1988 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի մարտին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
[D-Arg1,D-Phe5,D-Trp7,9,Leu11] ...... ll lung cancer cells in vitro.
@ast
[D-Arg1,D-Phe5,D-Trp7,9,Leu11] ...... ll lung cancer cells in vitro.
@en
[D-Arg1,D-Phe5,D-Trp7,9,Leu11] ...... ll lung cancer cells in vitro.
@nl
type
label
[D-Arg1,D-Phe5,D-Trp7,9,Leu11] ...... ll lung cancer cells in vitro.
@ast
[D-Arg1,D-Phe5,D-Trp7,9,Leu11] ...... ll lung cancer cells in vitro.
@en
[D-Arg1,D-Phe5,D-Trp7,9,Leu11] ...... ll lung cancer cells in vitro.
@nl
prefLabel
[D-Arg1,D-Phe5,D-Trp7,9,Leu11] ...... ll lung cancer cells in vitro.
@ast
[D-Arg1,D-Phe5,D-Trp7,9,Leu11] ...... ll lung cancer cells in vitro.
@en
[D-Arg1,D-Phe5,D-Trp7,9,Leu11] ...... ll lung cancer cells in vitro.
@nl
P2860
P356
P1476
[D-Arg1,D-Phe5,D-Trp7,9,Leu11] ...... ll lung cancer cells in vitro.
@en
P2093
P2860
P304
P356
10.1073/PNAS.85.6.1859
P407
P577
1988-03-01T00:00:00Z